nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—CYP3A4—bone cancer	0.865	1	CbGaD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—JUN—bone cancer	0.00245	0.162	CbGpPWpGaD
Dantrolene—Pericarditis—Methotrexate—bone cancer	0.00173	0.0144	CcSEcCtD
Dantrolene—Pericarditis—Epirubicin—bone cancer	0.00162	0.0135	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00161	0.107	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—RGS1—bone cancer	0.00156	0.104	CbGpPWpGaD
Dantrolene—Extravasation—Cisplatin—bone cancer	0.00156	0.013	CcSEcCtD
Dantrolene—Pericarditis—Doxorubicin—bone cancer	0.00149	0.0125	CcSEcCtD
Dantrolene—Pain—Carboplatin—bone cancer	0.00141	0.0118	CcSEcCtD
Dantrolene—Body temperature increased—Carboplatin—bone cancer	0.00131	0.0109	CcSEcCtD
Dantrolene—Eruption—Methotrexate—bone cancer	0.00121	0.0101	CcSEcCtD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00119	0.0788	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—RGS1—bone cancer	0.00115	0.0763	CbGpPWpGaD
Dantrolene—Phlebitis—Cisplatin—bone cancer	0.00115	0.00955	CcSEcCtD
Dantrolene—Eruption—Epirubicin—bone cancer	0.00114	0.00946	CcSEcCtD
Dantrolene—Eruption—Doxorubicin—bone cancer	0.00105	0.00876	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.000987	0.00823	CcSEcCtD
Dantrolene—Pleural effusion—Methotrexate—bone cancer	0.000975	0.00812	CcSEcCtD
Dantrolene—Hepatotoxicity—Methotrexate—bone cancer	0.000967	0.00806	CcSEcCtD
Dantrolene—Necrosis—Methotrexate—bone cancer	0.000951	0.00793	CcSEcCtD
Dantrolene—Pleural effusion—Epirubicin—bone cancer	0.000912	0.0076	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000902	0.0597	CbGpPWpGaD
Dantrolene—Necrosis—Epirubicin—bone cancer	0.00089	0.00742	CcSEcCtD
Dantrolene—Speech disorder—Methotrexate—bone cancer	0.000868	0.00723	CcSEcCtD
Dantrolene—Extravasation—Methotrexate—bone cancer	0.000855	0.00713	CcSEcCtD
Dantrolene—Dysphonia—Epirubicin—bone cancer	0.000849	0.00708	CcSEcCtD
Dantrolene—Pleural effusion—Doxorubicin—bone cancer	0.000844	0.00703	CcSEcCtD
Dantrolene—Necrosis—Doxorubicin—bone cancer	0.000823	0.00686	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—ATF1—bone cancer	0.000813	0.0538	CbGpPWpGaD
Dantrolene—Extravasation—Epirubicin—bone cancer	0.000801	0.00667	CcSEcCtD
Dantrolene—Dysphonia—Doxorubicin—bone cancer	0.000786	0.00655	CcSEcCtD
Dantrolene—Respiratory failure—Methotrexate—bone cancer	0.00076	0.00633	CcSEcCtD
Dantrolene—Lacrimation increased—Epirubicin—bone cancer	0.000758	0.00632	CcSEcCtD
Dantrolene—Nocturia—Epirubicin—bone cancer	0.000753	0.00628	CcSEcCtD
Dantrolene—Renal failure—Cisplatin—bone cancer	0.000748	0.00623	CcSEcCtD
Dantrolene—Extravasation—Doxorubicin—bone cancer	0.000741	0.00617	CcSEcCtD
Dantrolene—Atrioventricular block—Epirubicin—bone cancer	0.00072	0.006	CcSEcCtD
Dantrolene—Lacrimation increased—Doxorubicin—bone cancer	0.000701	0.00585	CcSEcCtD
Dantrolene—Aplastic anaemia—Methotrexate—bone cancer	0.000701	0.00584	CcSEcCtD
Dantrolene—Nocturia—Doxorubicin—bone cancer	0.000697	0.00581	CcSEcCtD
Dantrolene—Injection site reaction—Epirubicin—bone cancer	0.000694	0.00579	CcSEcCtD
Dantrolene—Atrioventricular block—Doxorubicin—bone cancer	0.000666	0.00555	CcSEcCtD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000665	0.044	CbGpPWpGaD
Dantrolene—Pulmonary oedema—Methotrexate—bone cancer	0.000664	0.00554	CcSEcCtD
Dantrolene—Visual impairment—Cisplatin—bone cancer	0.000658	0.00549	CcSEcCtD
Dantrolene—Aplastic anaemia—Epirubicin—bone cancer	0.000656	0.00547	CcSEcCtD
Dantrolene—Injection site reaction—Doxorubicin—bone cancer	0.000642	0.00535	CcSEcCtD
Dantrolene—Flushing—Cisplatin—bone cancer	0.000634	0.00528	CcSEcCtD
Dantrolene—Thrombophlebitis—Methotrexate—bone cancer	0.000626	0.00522	CcSEcCtD
Dantrolene—Pulmonary oedema—Epirubicin—bone cancer	0.000622	0.00518	CcSEcCtD
Dantrolene—Aplastic anaemia—Doxorubicin—bone cancer	0.000607	0.00506	CcSEcCtD
Dantrolene—Hepatic failure—Methotrexate—bone cancer	0.000603	0.00502	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—ATF1—bone cancer	0.000599	0.0396	CbGpPWpGaD
Dantrolene—Erythema—Cisplatin—bone cancer	0.000595	0.00496	CcSEcCtD
Dantrolene—Phlebitis—Epirubicin—bone cancer	0.000589	0.00491	CcSEcCtD
Dantrolene—Thrombophlebitis—Epirubicin—bone cancer	0.000586	0.00488	CcSEcCtD
Dantrolene—Pulmonary oedema—Doxorubicin—bone cancer	0.000575	0.00479	CcSEcCtD
Dantrolene—Visual disturbance—Methotrexate—bone cancer	0.000572	0.00477	CcSEcCtD
Dantrolene—Hepatic failure—Epirubicin—bone cancer	0.000564	0.0047	CcSEcCtD
Dantrolene—Vision blurred—Cisplatin—bone cancer	0.00056	0.00467	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000559	0.037	CbGpPWpGaD
Dantrolene—Ill-defined disorder—Cisplatin—bone cancer	0.000552	0.0046	CcSEcCtD
Dantrolene—Anaemia—Cisplatin—bone cancer	0.00055	0.00458	CcSEcCtD
Dantrolene—Phlebitis—Doxorubicin—bone cancer	0.000545	0.00454	CcSEcCtD
Dantrolene—Thrombophlebitis—Doxorubicin—bone cancer	0.000542	0.00452	CcSEcCtD
Dantrolene—Malaise—Cisplatin—bone cancer	0.000536	0.00447	CcSEcCtD
Dantrolene—Leukopenia—Cisplatin—bone cancer	0.000532	0.00444	CcSEcCtD
Dantrolene—Hepatic failure—Doxorubicin—bone cancer	0.000522	0.00435	CcSEcCtD
Dantrolene—Cardiac failure—Epirubicin—bone cancer	0.00052	0.00433	CcSEcCtD
Dantrolene—Convulsion—Cisplatin—bone cancer	0.000515	0.00429	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000507	0.00423	CcSEcCtD
Dantrolene—Diplopia—Epirubicin—bone cancer	0.000507	0.00423	CcSEcCtD
Dantrolene—Pain in extremity—Epirubicin—bone cancer	0.000507	0.00423	CcSEcCtD
Dantrolene—Myalgia—Cisplatin—bone cancer	0.000506	0.00422	CcSEcCtD
Dantrolene—Discomfort—Cisplatin—bone cancer	0.0005	0.00417	CcSEcCtD
Dantrolene—Anaphylactic shock—Cisplatin—bone cancer	0.000485	0.00404	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000483	0.0319	CbGpPWpGaD
Dantrolene—Cardiac failure—Doxorubicin—bone cancer	0.000481	0.00401	CcSEcCtD
Dantrolene—Thrombocytopenia—Cisplatin—bone cancer	0.000475	0.00396	CcSEcCtD
Dantrolene—Tachycardia—Cisplatin—bone cancer	0.000474	0.00395	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000469	0.00391	CcSEcCtD
Dantrolene—Pain in extremity—Doxorubicin—bone cancer	0.000469	0.00391	CcSEcCtD
Dantrolene—Diplopia—Doxorubicin—bone cancer	0.000469	0.00391	CcSEcCtD
Dantrolene—Hyperhidrosis—Cisplatin—bone cancer	0.000469	0.00391	CcSEcCtD
Dantrolene—Eosinophilia—Methotrexate—bone cancer	0.000464	0.00386	CcSEcCtD
Dantrolene—Anorexia—Cisplatin—bone cancer	0.000463	0.00386	CcSEcCtD
Dantrolene—Muscular weakness—Epirubicin—bone cancer	0.000447	0.00373	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000442	0.00368	CcSEcCtD
Dantrolene—Dysphagia—Epirubicin—bone cancer	0.000438	0.00365	CcSEcCtD
Dantrolene—Eosinophilia—Epirubicin—bone cancer	0.000434	0.00362	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000432	0.0286	CbGpPWpGaD
Dantrolene—Decreased appetite—Cisplatin—bone cancer	0.000422	0.00352	CcSEcCtD
Dantrolene—Drowsiness—Methotrexate—bone cancer	0.000418	0.00348	CcSEcCtD
Dantrolene—Depression—Methotrexate—bone cancer	0.000416	0.00347	CcSEcCtD
Dantrolene—Pain—Cisplatin—bone cancer	0.000415	0.00346	CcSEcCtD
Dantrolene—Muscular weakness—Doxorubicin—bone cancer	0.000414	0.00345	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000412	0.0273	CbGpPWpGaD
Dantrolene—Renal failure—Methotrexate—bone cancer	0.00041	0.00342	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000406	0.0269	CbGpPWpGaD
Dantrolene—Dysphagia—Doxorubicin—bone cancer	0.000405	0.00338	CcSEcCtD
Dantrolene—Pollakiuria—Epirubicin—bone cancer	0.000405	0.00337	CcSEcCtD
Dantrolene—Eosinophilia—Doxorubicin—bone cancer	0.000401	0.00335	CcSEcCtD
Dantrolene—Sweating—Methotrexate—bone cancer	0.0004	0.00334	CcSEcCtD
Dantrolene—Feeling abnormal—Cisplatin—bone cancer	0.0004	0.00333	CcSEcCtD
Dantrolene—Haematuria—Methotrexate—bone cancer	0.000398	0.00332	CcSEcCtD
Dantrolene—Drowsiness—Epirubicin—bone cancer	0.000391	0.00326	CcSEcCtD
Dantrolene—Renal failure—Epirubicin—bone cancer	0.000384	0.0032	CcSEcCtD
Dantrolene—Body temperature increased—Cisplatin—bone cancer	0.000384	0.0032	CcSEcCtD
Dantrolene—Haemoglobin—Methotrexate—bone cancer	0.000377	0.00314	CcSEcCtD
Dantrolene—Haemorrhage—Methotrexate—bone cancer	0.000375	0.00312	CcSEcCtD
Dantrolene—Hepatitis—Methotrexate—bone cancer	0.000375	0.00312	CcSEcCtD
Dantrolene—Sweating—Epirubicin—bone cancer	0.000375	0.00312	CcSEcCtD
Dantrolene—Pollakiuria—Doxorubicin—bone cancer	0.000375	0.00312	CcSEcCtD
Dantrolene—Haematuria—Epirubicin—bone cancer	0.000373	0.00311	CcSEcCtD
Dantrolene—Drowsiness—Doxorubicin—bone cancer	0.000362	0.00301	CcSEcCtD
Dantrolene—Visual impairment—Methotrexate—bone cancer	0.000361	0.00301	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TP53—bone cancer	0.000358	0.0237	CbGpPWpGaD
Dantrolene—Hypersensitivity—Cisplatin—bone cancer	0.000358	0.00298	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000356	0.0235	CbGpPWpGaD
Dantrolene—Renal failure—Doxorubicin—bone cancer	0.000355	0.00296	CcSEcCtD
Dantrolene—Haemoglobin—Epirubicin—bone cancer	0.000353	0.00294	CcSEcCtD
Dantrolene—Hepatitis—Epirubicin—bone cancer	0.000351	0.00292	CcSEcCtD
Dantrolene—Haemorrhage—Epirubicin—bone cancer	0.000351	0.00292	CcSEcCtD
Dantrolene—Asthenia—Cisplatin—bone cancer	0.000348	0.0029	CcSEcCtD
Dantrolene—Sweating—Doxorubicin—bone cancer	0.000347	0.00289	CcSEcCtD
Dantrolene—Haematuria—Doxorubicin—bone cancer	0.000345	0.00287	CcSEcCtD
Dantrolene—Visual impairment—Epirubicin—bone cancer	0.000338	0.00282	CcSEcCtD
Dantrolene—Chills—Methotrexate—bone cancer	0.000336	0.0028	CcSEcCtD
Dantrolene—Diarrhoea—Cisplatin—bone cancer	0.000332	0.00277	CcSEcCtD
Dantrolene—Erythema—Methotrexate—bone cancer	0.000326	0.00272	CcSEcCtD
Dantrolene—Haemoglobin—Doxorubicin—bone cancer	0.000326	0.00272	CcSEcCtD
Dantrolene—Flushing—Epirubicin—bone cancer	0.000326	0.00271	CcSEcCtD
Dantrolene—Hepatitis—Doxorubicin—bone cancer	0.000325	0.00271	CcSEcCtD
Dantrolene—Haemorrhage—Doxorubicin—bone cancer	0.000325	0.00271	CcSEcCtD
Dantrolene—Dysgeusia—Methotrexate—bone cancer	0.00032	0.00266	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—JUN—bone cancer	0.000317	0.021	CbGpPWpGaD
Dantrolene—Back pain—Methotrexate—bone cancer	0.000316	0.00263	CcSEcCtD
Dantrolene—Chills—Epirubicin—bone cancer	0.000315	0.00262	CcSEcCtD
Dantrolene—Visual impairment—Doxorubicin—bone cancer	0.000313	0.00261	CcSEcCtD
Dantrolene—Vomiting—Cisplatin—bone cancer	0.000309	0.00257	CcSEcCtD
Dantrolene—Vision blurred—Methotrexate—bone cancer	0.000307	0.00256	CcSEcCtD
Dantrolene—Rash—Cisplatin—bone cancer	0.000306	0.00255	CcSEcCtD
Dantrolene—Dermatitis—Cisplatin—bone cancer	0.000306	0.00255	CcSEcCtD
Dantrolene—Erythema—Epirubicin—bone cancer	0.000305	0.00254	CcSEcCtD
Dantrolene—Ill-defined disorder—Methotrexate—bone cancer	0.000303	0.00252	CcSEcCtD
Dantrolene—Anaemia—Methotrexate—bone cancer	0.000302	0.00251	CcSEcCtD
Dantrolene—Flushing—Doxorubicin—bone cancer	0.000301	0.00251	CcSEcCtD
Dantrolene—Tension—Epirubicin—bone cancer	0.0003	0.0025	CcSEcCtD
Dantrolene—Dysgeusia—Epirubicin—bone cancer	0.000299	0.00249	CcSEcCtD
Dantrolene—Nervousness—Epirubicin—bone cancer	0.000297	0.00247	CcSEcCtD
Dantrolene—Back pain—Epirubicin—bone cancer	0.000295	0.00246	CcSEcCtD
Dantrolene—Malaise—Methotrexate—bone cancer	0.000294	0.00245	CcSEcCtD
Dantrolene—Leukopenia—Methotrexate—bone cancer	0.000292	0.00243	CcSEcCtD
Dantrolene—Chills—Doxorubicin—bone cancer	0.000291	0.00243	CcSEcCtD
Dantrolene—Nausea—Cisplatin—bone cancer	0.000288	0.0024	CcSEcCtD
Dantrolene—Vision blurred—Epirubicin—bone cancer	0.000288	0.0024	CcSEcCtD
Dantrolene—Ill-defined disorder—Epirubicin—bone cancer	0.000283	0.00236	CcSEcCtD
Dantrolene—Convulsion—Methotrexate—bone cancer	0.000283	0.00236	CcSEcCtD
Dantrolene—Erythema—Doxorubicin—bone cancer	0.000283	0.00235	CcSEcCtD
Dantrolene—Anaemia—Epirubicin—bone cancer	0.000282	0.00235	CcSEcCtD
Dantrolene—Myalgia—Methotrexate—bone cancer	0.000278	0.00232	CcSEcCtD
Dantrolene—Tension—Doxorubicin—bone cancer	0.000277	0.00231	CcSEcCtD
Dantrolene—Dysgeusia—Doxorubicin—bone cancer	0.000277	0.00231	CcSEcCtD
Dantrolene—Malaise—Epirubicin—bone cancer	0.000275	0.00229	CcSEcCtD
Dantrolene—Discomfort—Methotrexate—bone cancer	0.000274	0.00229	CcSEcCtD
Dantrolene—Nervousness—Doxorubicin—bone cancer	0.000274	0.00229	CcSEcCtD
Dantrolene—Leukopenia—Epirubicin—bone cancer	0.000273	0.00228	CcSEcCtD
Dantrolene—Back pain—Doxorubicin—bone cancer	0.000273	0.00228	CcSEcCtD
Dantrolene—Confusional state—Methotrexate—bone cancer	0.000269	0.00224	CcSEcCtD
Dantrolene—Anaphylactic shock—Methotrexate—bone cancer	0.000266	0.00222	CcSEcCtD
Dantrolene—Vision blurred—Doxorubicin—bone cancer	0.000266	0.00222	CcSEcCtD
Dantrolene—Convulsion—Epirubicin—bone cancer	0.000265	0.0022	CcSEcCtD
Dantrolene—Hypertension—Epirubicin—bone cancer	0.000264	0.0022	CcSEcCtD
Dantrolene—Ill-defined disorder—Doxorubicin—bone cancer	0.000262	0.00218	CcSEcCtD
Dantrolene—Anaemia—Doxorubicin—bone cancer	0.000261	0.00218	CcSEcCtD
Dantrolene—Thrombocytopenia—Methotrexate—bone cancer	0.000261	0.00217	CcSEcCtD
Dantrolene—Myalgia—Epirubicin—bone cancer	0.00026	0.00217	CcSEcCtD
Dantrolene—Hyperhidrosis—Methotrexate—bone cancer	0.000257	0.00215	CcSEcCtD
Dantrolene—Discomfort—Epirubicin—bone cancer	0.000257	0.00214	CcSEcCtD
Dantrolene—Malaise—Doxorubicin—bone cancer	0.000255	0.00212	CcSEcCtD
Dantrolene—Dry mouth—Epirubicin—bone cancer	0.000254	0.00212	CcSEcCtD
Dantrolene—Anorexia—Methotrexate—bone cancer	0.000254	0.00212	CcSEcCtD
Dantrolene—Leukopenia—Doxorubicin—bone cancer	0.000253	0.00211	CcSEcCtD
Dantrolene—Confusional state—Epirubicin—bone cancer	0.000251	0.00209	CcSEcCtD
Dantrolene—Anaphylactic shock—Epirubicin—bone cancer	0.000249	0.00208	CcSEcCtD
Dantrolene—Convulsion—Doxorubicin—bone cancer	0.000245	0.00204	CcSEcCtD
Dantrolene—Thrombocytopenia—Epirubicin—bone cancer	0.000244	0.00203	CcSEcCtD
Dantrolene—Hypertension—Doxorubicin—bone cancer	0.000244	0.00203	CcSEcCtD
Dantrolene—Tachycardia—Epirubicin—bone cancer	0.000243	0.00203	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000243	0.00202	CcSEcCtD
Dantrolene—Hyperhidrosis—Epirubicin—bone cancer	0.000241	0.00201	CcSEcCtD
Dantrolene—Insomnia—Methotrexate—bone cancer	0.000241	0.00201	CcSEcCtD
Dantrolene—Myalgia—Doxorubicin—bone cancer	0.000241	0.002	CcSEcCtD
Dantrolene—Discomfort—Doxorubicin—bone cancer	0.000238	0.00198	CcSEcCtD
Dantrolene—Anorexia—Epirubicin—bone cancer	0.000238	0.00198	CcSEcCtD
Dantrolene—Somnolence—Methotrexate—bone cancer	0.000237	0.00197	CcSEcCtD
Dantrolene—Dry mouth—Doxorubicin—bone cancer	0.000235	0.00196	CcSEcCtD
Dantrolene—Dyspepsia—Methotrexate—bone cancer	0.000234	0.00195	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—JUN—bone cancer	0.000233	0.0154	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000233	0.0154	CbGpPWpGaD
Dantrolene—Confusional state—Doxorubicin—bone cancer	0.000232	0.00194	CcSEcCtD
Dantrolene—Decreased appetite—Methotrexate—bone cancer	0.000231	0.00193	CcSEcCtD
Dantrolene—Anaphylactic shock—Doxorubicin—bone cancer	0.000231	0.00192	CcSEcCtD
Dantrolene—Fatigue—Methotrexate—bone cancer	0.00023	0.00191	CcSEcCtD
Dantrolene—Pain—Methotrexate—bone cancer	0.000228	0.0019	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000227	0.00189	CcSEcCtD
Dantrolene—Thrombocytopenia—Doxorubicin—bone cancer	0.000226	0.00188	CcSEcCtD
Dantrolene—Insomnia—Epirubicin—bone cancer	0.000225	0.00188	CcSEcCtD
Dantrolene—Tachycardia—Doxorubicin—bone cancer	0.000225	0.00188	CcSEcCtD
Dantrolene—Hyperhidrosis—Doxorubicin—bone cancer	0.000223	0.00186	CcSEcCtD
Dantrolene—Somnolence—Epirubicin—bone cancer	0.000222	0.00185	CcSEcCtD
Dantrolene—Anorexia—Doxorubicin—bone cancer	0.00022	0.00183	CcSEcCtD
Dantrolene—Feeling abnormal—Methotrexate—bone cancer	0.000219	0.00183	CcSEcCtD
Dantrolene—Dyspepsia—Epirubicin—bone cancer	0.000219	0.00183	CcSEcCtD
Dantrolene—Gastrointestinal pain—Methotrexate—bone cancer	0.000218	0.00181	CcSEcCtD
Dantrolene—Decreased appetite—Epirubicin—bone cancer	0.000217	0.00181	CcSEcCtD
Dantrolene—Fatigue—Epirubicin—bone cancer	0.000215	0.00179	CcSEcCtD
Dantrolene—Constipation—Epirubicin—bone cancer	0.000213	0.00178	CcSEcCtD
Dantrolene—Pain—Epirubicin—bone cancer	0.000213	0.00178	CcSEcCtD
Dantrolene—Urticaria—Methotrexate—bone cancer	0.000212	0.00176	CcSEcCtD
Dantrolene—Abdominal pain—Methotrexate—bone cancer	0.000211	0.00175	CcSEcCtD
Dantrolene—Body temperature increased—Methotrexate—bone cancer	0.000211	0.00175	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00021	0.00175	CcSEcCtD
Dantrolene—Insomnia—Doxorubicin—bone cancer	0.000209	0.00174	CcSEcCtD
Dantrolene—Feeling abnormal—Epirubicin—bone cancer	0.000205	0.00171	CcSEcCtD
Dantrolene—Somnolence—Doxorubicin—bone cancer	0.000205	0.00171	CcSEcCtD
Dantrolene—Gastrointestinal pain—Epirubicin—bone cancer	0.000204	0.0017	CcSEcCtD
Dantrolene—Dyspepsia—Doxorubicin—bone cancer	0.000203	0.00169	CcSEcCtD
Dantrolene—Decreased appetite—Doxorubicin—bone cancer	0.0002	0.00167	CcSEcCtD
Dantrolene—Fatigue—Doxorubicin—bone cancer	0.000199	0.00166	CcSEcCtD
Dantrolene—Urticaria—Epirubicin—bone cancer	0.000198	0.00165	CcSEcCtD
Dantrolene—Pain—Doxorubicin—bone cancer	0.000197	0.00164	CcSEcCtD
Dantrolene—Constipation—Doxorubicin—bone cancer	0.000197	0.00164	CcSEcCtD
Dantrolene—Abdominal pain—Epirubicin—bone cancer	0.000197	0.00164	CcSEcCtD
Dantrolene—Body temperature increased—Epirubicin—bone cancer	0.000197	0.00164	CcSEcCtD
Dantrolene—Hypersensitivity—Methotrexate—bone cancer	0.000196	0.00164	CcSEcCtD
Dantrolene—Asthenia—Methotrexate—bone cancer	0.000191	0.00159	CcSEcCtD
Dantrolene—Feeling abnormal—Doxorubicin—bone cancer	0.00019	0.00158	CcSEcCtD
Dantrolene—Gastrointestinal pain—Doxorubicin—bone cancer	0.000189	0.00157	CcSEcCtD
Dantrolene—Pruritus—Methotrexate—bone cancer	0.000188	0.00157	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000186	0.0123	CbGpPWpGaD
Dantrolene—Hypersensitivity—Epirubicin—bone cancer	0.000184	0.00153	CcSEcCtD
Dantrolene—Urticaria—Doxorubicin—bone cancer	0.000183	0.00153	CcSEcCtD
Dantrolene—Abdominal pain—Doxorubicin—bone cancer	0.000182	0.00152	CcSEcCtD
Dantrolene—Body temperature increased—Doxorubicin—bone cancer	0.000182	0.00152	CcSEcCtD
Dantrolene—Diarrhoea—Methotrexate—bone cancer	0.000182	0.00152	CcSEcCtD
Dantrolene—Asthenia—Epirubicin—bone cancer	0.000179	0.00149	CcSEcCtD
Dantrolene—Pruritus—Epirubicin—bone cancer	0.000176	0.00147	CcSEcCtD
Dantrolene—Dizziness—Methotrexate—bone cancer	0.000176	0.00147	CcSEcCtD
Dantrolene—Diarrhoea—Epirubicin—bone cancer	0.000171	0.00142	CcSEcCtD
Dantrolene—Hypersensitivity—Doxorubicin—bone cancer	0.00017	0.00142	CcSEcCtD
Dantrolene—Vomiting—Methotrexate—bone cancer	0.000169	0.00141	CcSEcCtD
Dantrolene—Rash—Methotrexate—bone cancer	0.000168	0.0014	CcSEcCtD
Dantrolene—Dermatitis—Methotrexate—bone cancer	0.000168	0.0014	CcSEcCtD
Dantrolene—Headache—Methotrexate—bone cancer	0.000167	0.00139	CcSEcCtD
Dantrolene—Asthenia—Doxorubicin—bone cancer	0.000165	0.00138	CcSEcCtD
Dantrolene—Dizziness—Epirubicin—bone cancer	0.000165	0.00137	CcSEcCtD
Dantrolene—Pruritus—Doxorubicin—bone cancer	0.000163	0.00136	CcSEcCtD
Dantrolene—Vomiting—Epirubicin—bone cancer	0.000158	0.00132	CcSEcCtD
Dantrolene—Nausea—Methotrexate—bone cancer	0.000158	0.00132	CcSEcCtD
Dantrolene—Diarrhoea—Doxorubicin—bone cancer	0.000158	0.00131	CcSEcCtD
Dantrolene—Rash—Epirubicin—bone cancer	0.000157	0.00131	CcSEcCtD
Dantrolene—Dermatitis—Epirubicin—bone cancer	0.000157	0.00131	CcSEcCtD
Dantrolene—Headache—Epirubicin—bone cancer	0.000156	0.0013	CcSEcCtD
Dantrolene—Dizziness—Doxorubicin—bone cancer	0.000152	0.00127	CcSEcCtD
Dantrolene—Nausea—Epirubicin—bone cancer	0.000148	0.00123	CcSEcCtD
Dantrolene—Vomiting—Doxorubicin—bone cancer	0.000147	0.00122	CcSEcCtD
Dantrolene—Rash—Doxorubicin—bone cancer	0.000145	0.00121	CcSEcCtD
Dantrolene—Dermatitis—Doxorubicin—bone cancer	0.000145	0.00121	CcSEcCtD
Dantrolene—Headache—Doxorubicin—bone cancer	0.000144	0.0012	CcSEcCtD
Dantrolene—Nausea—Doxorubicin—bone cancer	0.000137	0.00114	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.92e-05	0.00325	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.19e-05	0.00211	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.14e-05	0.00208	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NDUFA12—bone cancer	2.23e-05	0.00148	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NT5C3A—bone cancer	1.85e-05	0.00122	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ENO2—bone cancer	8.1e-06	0.000536	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—DHFR—bone cancer	7.52e-06	0.000498	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GNA11—bone cancer	7.03e-06	0.000465	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTP1—bone cancer	5.45e-06	0.000361	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—bone cancer	2.82e-06	0.000187	CbGpPWpGaD
